Free Trial

Celldex Therapeutics Q2 2023 Earnings Report

Celldex Therapeutics logo
$23.68 +0.93 (+4.06%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Celldex Therapeutics EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.65
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$0.67 million
Beat/Miss
Missed by -$400.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Celldex Therapeutics Earnings Headlines

Tesla Shares Soar After Trump Win (Act Now)
Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.
Celldex initates Phase 2 study of barzolvolimab in AD
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat